

Aggressive MS

THURSDAY, 1 MARCH 2018

- 08.30 - 08.45** **Welcome from ECTRIMS president**
D. Miller (London, UK)
- 08.45 - 09.45** **Session 1: How to define aggressive MS**
Chairs: H. Tremlett (Vancouver, CA), M. S. Freedman (Ottawa, CA)
Definition of aggressive MS
- 08.45 At disease onset: bad relapse versus bad outcome
L. Brundin (Stockholm, SE)
- 09.05 In treated patients with relapsing and progressive MS
E. Havrdová (Prague, CZ)
- 09.35 – 10.05** **Roundtable/Panel discussion 1: Consensus/controversies on aggressive MS definition**
Panel members: H. Tremlett (Vancouver, CA), M. S. Freedman (Ottawa, CA), L. Brundin (Stockholm, SE), E. Havrdová (Prague, CZ), X. Montalban (Barcelona, ES)
- 10.05 – 10.35** **Coffee break**
- 10.35 – 11.35** **Session 1: How to define aggressive MS (continued)**
Chairs: H. Tremlett (Vancouver, CA), M. S. Freedman (Ottawa, CA)
Epidemiology and pathophysiology of aggressive MS
- 10.35 Regional differences
H.J. Kim (Seoul, KR)
- 10.55 Pathology
B. Trapp (Cleveland, US)
- 11.15 Immunology
R. Liblau (Toulouse, FR)

- 11.35 – 12.15** **Session 2: Can we predict aggressive MS: lessons from real world data**
Chairs: M. Trojano (Bari, IT), J. Hillert (Stockholm, SE)
- 11.35 Long term cohorts
M. Tintore (Barcelona, ES)
- 11.55 Registries
T. Kalincik (Melbourne, AU)
- 12.15 - 13.00** **Roundtable/Panel discussion 2: Is modelling the course and outcomes
of MS feasible?**
*Panel members: M. Trojano (Bari, IT), J. Hillert (Stockholm, SE), M. Tintore
(Barcelona, ES), T. Kalincik (Melbourne, AU)*
- 13.00 - 14.00** **Lunch break**
- 14.00 - 16.00** **Session 3: How to manage aggressive MS**
Chairs: H.P. Hartung (Düsseldorf, DE), M. P. Amato (Florence, IT)
- 14.00 How to communicate aggressive MS: which are the limits and the range of
error: counselling in delivering bad news
A. Solari (Milan, IT)
- 14.20 Treatment of severe relapses
R. Gold (Bochum, DE)
- 14.40 Is there a place for orals?
S. Vukusic (Lyon, FR)
- 15.00 Is there a place for Monoclonal Abs
B. Hemmer (Munich, DE)
- 15.20 Is there a place for BMT
P. Muraro (London, UK)
- 15.40 Management of aggressive, progressive MS *(via video conference)*
X. Montalban (Toronto, CA)
- 16.00 - 16.30** **Coffee break**

- 16.30 – 17.30** **Session 3: How to manage aggressive MS (continued)**
Chairs: H.P. Hartung (Düsseldorf, DE), M. P. Amato (Florence, IT)
- 16.30 Out boundaries: How would you treat aggressive MS
K. Schmierer (London, UK)
- 16.50 Specific situations in pregnancy
K. Hellwig (Bochum, DE)
- 17.10 Specific situations in children
E. Waubant (San Francisco, US)
- 17.30 Specific situations in senior patients – using population-based data to
highlight opportunity and need
H. Tremlett (Vancouver, CA)
- 17.50 - 18.20** **Roundtable/Panel discussion 3: Treatments strategies**
*Panel members: H.P. Hartung (Düsseldorf, DE) M. P. Amato (Florence, IT),
A. Solari (Milan, IT), R. Gold (Bochum, DE), S. Vukusic (Lyon, FR),
B. Hemmer (Munich, DE), P. Muraro (London, UK), K. Schmierer
(London, UK), K. Hellwig (Bochum, DE), E. Waubant (San Francisco, US),
H. Tremlett (Vancouver, CA)*
- 18.20 - 18.30** **Wrap-up day 1**
L. Brundin (Stockholm, SE)
- 19.30** **Workshop Dinner**

FRIDAY, 2 March 2018

- 08.30 - 09.50** **Session 4: How to make progress in aggressive MS**
Chairs: A. Thompson (London, UK), L. Kappos (Basel, CH)
- 08.30 MRI contribution
O. Ciccarelli (London, UK)
- 08.50 Biomarkers contribution
T. Derfuss (Basel, CH)
- 09.10 New trial design
G. Cutter (Birmingham, UK)

- 09.30 New drugs
L. Kappos (Basel, CH)
- 09.50 - 10.30 Roundtable/Panel discussion 4: Moving forward**
*Panel members: A. Thompson (London, UK), T. Derfuss (Basel, CH),
G. Cutter (Birmingham, UK), O. Ciccarelli (London, UK), L. Kappos (Basel,
CH)*
- 10.30 - 11.00 Coffee break**
- 11.00 - 12.00 Session 5: How to manage and prevent complications of high efficacy
treatments**
Chairs: R. Gold (Bochum, DE), P. Soelberg Sørensen (Copenhagen, DK)
Infectious risk in patients with biologicals or other immunosuppressive
drugs
- 11.00 PML
J. Berger (Philadelphia, US)
- 11.20 Cancer, Papiloma V, listeria and other infections
A.J. Coles (Cambridge, UK)
Preventive strategies: Treatment of latent / pre-existing infections
- 11.40 Vaccination: which and when and travel advise
J. L. Fredriksen (Copenhagen, DK)
- 12.00 - 12.45 Roundtable/Panel discussion 5: Complications management and
preventive strategies**
*Panel members: R. Gold (Bochum, DE), P. Soelberg Sørensen (Copenhagen,
DK), J. Berger (Philadelphia, US), A.J. Coles (Cambridge, UK), J. L. Fredriksen
(Copenhagen, DK)*
- 12.45 - 13.45 Lunch break**
- 13.45 - 14.45 Meeting Summary**
M. Tintore (Barcelona, ES), B. Hemmer (Munich, DE)